Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study
| Autor: | Jing Ma, Tao Wang, Meilin Feng, Minke Shi, Lei Liang, Zhenghua Xie, Hongyuan Chen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Cancer Research Lung Neoplasms medicine.medical_treatment Biology DNA sequencing Targeted therapy 03 medical and health sciences Exon 0302 clinical medicine Carcinoma Non-Small-Cell Lung Genetics medicine Chromosomes Human Humans RNA Messenger Lung cancer Molecular Biology Aged Base Sequence Exons Middle Aged Proto-Oncogene Proteins c-met medicine.disease Reverse transcriptase Gene Expression Regulation Neoplastic 030220 oncology & carcinogenesis Mutation RNA splicing Cancer research Adenocarcinoma Female Tyrosine kinase |
| Zdroj: | Cancer Genetics. :62-67 |
| ISSN: | 2210-7762 |
| Popis: | MET exon 14 skipping (METex14) is a validated oncogenic driver in lung cancer and MET tyrosine kinase inhibitors are now available as effective clinical treatments. The majority of known METex14 alterations are typical donor/acceptor splicing or ubiquitination site mutations. Herein, two new METex14 variants were detected in two patients with lung adenocarcinoma by targeted next generation sequencing (NGS). Reverse transcription (RT)-based analysis confirmed that these mutations led to MET exon 14 skipping. Our analysis provided evidence for possible targeted therapy options for patients carrying these MET mutations or similar METex14 analogs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect